SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated June 16, 2025, it has closed the second and final tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”) of units of the Company (each